WO2000069446A1 - Polytherapie pour traiter l'hypercholesterolemie - Google Patents

Polytherapie pour traiter l'hypercholesterolemie Download PDF

Info

Publication number
WO2000069446A1
WO2000069446A1 PCT/US1999/010637 US9910637W WO0069446A1 WO 2000069446 A1 WO2000069446 A1 WO 2000069446A1 US 9910637 W US9910637 W US 9910637W WO 0069446 A1 WO0069446 A1 WO 0069446A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
amount
crosslinking agent
composition
hmg
Prior art date
Application number
PCT/US1999/010637
Other languages
English (en)
Inventor
Chad Cori Huval
Stephen Randall Holmes-Farley
John S. Petersen
Pradeep K. Dhal
Original Assignee
Geltex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharmaceuticals, Inc. filed Critical Geltex Pharmaceuticals, Inc.
Priority to PCT/US1999/010637 priority Critical patent/WO2000069446A1/fr
Priority to AU39903/99A priority patent/AU3990399A/en
Publication of WO2000069446A1 publication Critical patent/WO2000069446A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed.
  • the sequestered bile acids are excreted.
  • Compounds which have been suggested for bile acid sequestration include various ion exchange polymers.
  • One such polymer is cholestyramine, a copolymer of divinylbenzene and frimemylammoniummethyl styrene. It has been long recognized that this polymer is unpalatable, gritty, and constipating.
  • HMG Co-A reductase inhibitors include, for example, mevastatin (disclosed in U.S. Patent No. 3,883140), lovastatin, also referred to as mevinolin (disclosed in U.S. Patent No. 4,231,938), pravastatin (disclosed in U.S. Patent No. 4,346,227), simvastatin also referred to as synvinolin (disclosed in U.S. Patent Nos. 4,444,784 and 4,450,171), fluvastatin (disclosed in U.S. Patent No.
  • the invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal.
  • the methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound.
  • the first and second amounts together comprise a therapeutically effective amount.
  • the combination therapy can include other active agents for the treatment of hypercholesterolemia, atherosclerosis for reducing serum cholesterol, such as those described in U.S. Patent Application Serial No. (Attorney Docket)
  • the invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol.
  • the pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts comprise a therapeutically effective amount.
  • the pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier. Further, the pharmaceutical composition can contain other active agents for the treatment of hypercholesterolemia and atherosclerosis and for reducing serum cholesterol, such as those described in U.S. Patent Application Serial No. (Attorney Docket No. GTX97-23B, entitled Combination
  • the polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or more trialkylammonium alkyl groups.
  • the polymers are non- absorbable and optionally crosslinked.
  • the polymer is crosslinked by means of a multifunctional crosslinking agent.
  • the polymer can also be characterized as being linear or branched.
  • HMG Co-A Reductase Inhibitors useful in the present invention are listed in Table 1.
  • Each compound is present in the pharmaceutical composition in an amount which in combination with the other provides a therapeutically effective amount.
  • the pharmaceutical composition can include one or more of each class of compound.
  • the invention provides methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal.
  • the methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound.
  • the first and second amounts of said compounds together comprise a therapeutically effective amount.
  • the term "therapeutically effective amount" is intended to qualify the combined amount of the first and second compounds in the combination therapy.
  • the combined amount will achieve the desired biological response.
  • the desired biological response can be the treatment of hypercholesterolemia, the treatment of atherosclerosis and/or a reduction of serum cholesterol.
  • the mammal can be a human.
  • the polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or more trialkylammonium alkyl groups.
  • the polymers are non- absorbable and optionally crosslinked.
  • the polymer is crosslinked by means of a multifunctional crosslinking agent.
  • the polymer can also be characterized as being linear or branched.
  • the polymers employed in the method and pharmaceutical composition described herein comprise non-absorbable, optionally cross-linked polydiallylamines characterized by the formula above.
  • the polymers can be characterized by the substantial absence of substituted or unsubstituted alkyl substituents on the amino group of the monomer, such as obtained in the alkylation of an amine polymer. That is, the polymer can be characterized in that the polymer is substantially free of alkylated amine monomers.
  • the polymer can be a homopolymer or a copolymer. Where copolymers are manufactured with a diallylamine monomer, the comonomers are preferably inert, non-toxic and/or possess bile acid sequestration properties. Suitable examples of additional comonomers include substituted and unsubstituted acrylate, substituted and unsubstituted acrylamide, substituted and unsubstituted methacrylate, substituted and unsubstituted methacrylamide, allylamine, triallylamine, allyl alcohol, substituted and unsubstituted vinyl amine and substituted and unsubstituted vinyl alcohol. In one embodiment, the additional monomer is sulfur dioxide. Preferably, the monomers are aliphatic. Most preferably, the polymer is a homopolymer, i.e. a homopolydiallylamine.
  • the polymer is rendered water-insoluble by branching and/or crosslinking.
  • the cross-linking agent can be characterized by functional groups which react with the amino group of the monomer.
  • the crosslinking group can be characterized by two or more vinyl groups which undergo free radical polymerization with the amine monomer.
  • Suitable multifunctional co-monomers include triallylamine, tetraallylammonium salts, bis(diallylamine)s (such as alkylene bis(diallylamine)s), diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide and di(methacrylamides).
  • Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
  • the polymer can alternatively be crosslinked by bridging units which link amino groups on adjacent polymer strands.
  • Suitable bridging units include straight chain or branched, substituted or unsubstituted alkylene groups, diacylalkylene groups, diacylarene groups and alkylene bis(carbamoyl) groups.
  • Suitable bridging units include -(CH ) n -, wherein n is an integer from about 2 to about 20; - CH 2 -CH(OH)-CH 2 -; -C(O)CH 2 CH 2 C(O)-; -CH 2 -CH(OH)-O-(CH 2 ) n -O-CH(OH)-CH 2 - wherein n is 2 to about 4; -C(O)-(C 6 H 2 (COOH) 2 )-C(O)- and -C(O)NH(CH 2 ) p NHC(O)- , wherein p is an integer from about 2 to about 20.
  • crosslinking agents examples include acryloyl chloride, epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl succinate.
  • a preferred crosslinking agent is epichlorohydrin because of its high availability and low cost.
  • Epichlorohydrin is also advantageous because of its low molecular weight and hydrophilic nature, increasing the water-swellability of the polyamine.
  • the level of crosslinking makes the polymers insoluble and substantially resistant to absorption and degradation, thereby limiting the activity of the polymer to the gastrointestinal tract.
  • the compositions are non-systemic in their activity and will lead to reduced side-effects in the patient.
  • the cross-linking agent is present in an amount from about 0.5-50% (more preferably about 0.5-30% and most preferably about 2-20%) by weight, based upon total weight of monomer plus crosslinking agent.
  • polymers of use in the present method are, preferably, of a molecular weight which enables them to reach and remain in the gastrointestinal tract for a sufficient period of time to bind a significant amount of one or more bile acids.
  • polymers should, thus, be of sufficiently high molecular weight to resist, partially or completely, absorption from the gastrointestinal tract into other regions of the body.
  • the resulting polymer/bile salt complex should then be excreted from the body.
  • Suitable linear (non-crosslinked) polymers have molecular weights which range from about 2,000 Daltons to about 500,000 Daltons, preferably from about 5,000 Daltons to about 150,000 Daltons.
  • Crosslinked polymers are not generally characterized by molecular weight.
  • the crosslinked polymers discussed herein should be sufficiently crosslinked to resist adsorption from the gastrointestinal tract.
  • the polymer can be administered in the form of a salt, or as a partial salt.
  • salt it is meant that the nitrogen groups in all or some of the repeat units are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
  • the anionic counterions can be selected to minimize adverse effects on the patient, as is more particularly described below.
  • counterions examples include Cl “ , Br, CH 3 OSO 3 -, HSO 4 " , SO 4 2" , nitrate, HCO 3 " ,CO 3 --acetate, lactate, phosphate, hydrophosphate, methanesulfonate, fumarate, malate, pyruvate, malonate, benzoate, glucuronate, oxalate, acetylglycinate, succinate, propionate, butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, or a phospholipid.
  • the counterions can be the same as, or different from, each other.
  • the reaction product can contain two different types of counterions.
  • Polymers of use in the present method can be prepared using techniques known in the art of polymer synthesis (see for example, Shalaby et al, ed., Water- Soluble Polymers, American Chemical Society, Washington D.C. (1991)).
  • the appropriate monomer(s) can be polymerized by methods known in the art, for example, via a free radical addition process.
  • the polymerization mixture includes a free-radical initiator, such as a free radical initiator selected from among those which are well known in the art of polymer chemistry.
  • Suitable free- radical initiators include azobis(isobutyronitrile), azobis(4-cyanovaleric acid), azobis(amidinopropane) dihydrochloride, potassium persulfate, ammonium persulfate and potassium hydrogen persulfate.
  • the free radical initiator is preferably present in the reaction mixture in an amount ranging from about 0.1 mole percent to about 5 mole percent relative to the monomer.
  • the polymer can be crosslinked, for example, by including a multifunctional co-monomer as the crosslinking agent in the reaction mixture.
  • a multifunctional co- monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains.
  • Suitable multifunctional co-monomers include those discussed above.
  • the polymers can also be crosslinked subsequent to polymerization by reacting the polymer with one or more crosslinking agents having two or more functional groups, such as electrophilic groups, which react with amine groups to form a covalent bond.
  • Crosslinking in this case can occur, for example, via nucleophilic attack of the polymer amino groups on the electrophilic groups. This results in the formation of a bridging unit which links two or more amino nitrogen atoms from different polymer strands.
  • Suitable crosslinking agents of this type include compounds having two or more groups selected from among acyl-X, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group.
  • X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group.
  • Examples of such compounds include epichloro-hydrin, succinyl dichloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride and dihaloalkanes.
  • the crosslinking agent can also be an ⁇ , ⁇ -alkylene diisocyanate, for example OCN(CH 2 ) p NCO, wherein p is an integer from about 2 to about 20.
  • the polymer can also be crosslinked using a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain.
  • a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain.
  • examples include glycidyl methacrylate, glycidyl acrylate, acryloyl chloride, methacryloyl chloride, 3-bromopropylacrylate, 3-bromopropylmethyl- diallylammonium chloride, and 3-chloropropyldiallylamine.
  • the HMG Co- A- Reductase Inhibitors useful in the present invention are listed in Table 1.
  • NK-104 141750-63-2 Takano, Kamikubo, Sugihara, Suzuki, Ogasawara, -10-
  • Bile acid derived HMG CoA Kramer Wess, Enhsen, reductase inhibitors including Bock, Falk, Hoffmann, Na S-2467 and S-2468 Neckermann, Gantz, -14-
  • Atorvastatin Warner-Lambert cerivastatin Bayer bervastatin Merck KGaA BMS- 180431 Bristol-Myers Squibb NK-104 Nissan Chemical S-4522 Shionogi
  • HMG-CoA Reductase Inhibitors Bristol-Myers Squibb HMG-CoA Reductase Inhibitors Ono
  • HMG-CoA Reductase Inhibitors seco-oxysterol Pharmacia & Upjohn HMG-CoA Reductase Inhibitors, thiophene Sandoz
  • HMG-CoA Reductase Inhibitors 6-phenoxy- Hoechst Marion Roussel 3,5-dihydoxyhexanoic acids hypolipaemics, Warner-Lambert Warner-Lambert
  • the invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol.
  • the pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound.
  • the first and second amounts of said compounds comprise a therapeutically effective amount.
  • the pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.
  • combination therapy refers to administration of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound and/or other active agent to treat hypercholesterolemia and atherosclerosis, and reduce serum cholesterol.
  • Administration in combination therapy encompasses co- administration of the first and second amounts of the compounds of the combination therapy in a single substantially simultaneous manner, such as in a single capsule or tablet having a fixed ratio of first and second amounts, or in multiple, separate capsules or tablets for each.
  • administration also encompasses use of each compound in a sequential manner.
  • HMG Co-A reductase inhibitor and/or other active agent in combination therapy may be accomplished by oral route, or by intravenous, intramuscular, subcutaneous injections or a combination thereof.
  • the HMG Co-A reductase inhibitor and other active agent of the combination can be in the form of a bolus, or in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.
  • solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, for example, saline, dextrose, water or a combination thereof, or a binder such as gelatin or hydroxypropylmethyl cellulose, together with one or more of a lubricant, preservative, surface active or dispersing agent.
  • a pharmaceutically-acceptable carriers or diluents for example, saline, dextrose, water or a combination thereof, or a binder such as gelatin or hydroxypropylmethyl cellulose, together with one or more of a lubricant, preservative, surface active or dispersing agent.
  • the unsubstituted polydiallyamine polymer, HMG Co-A reductase inhibitor and/or other active agent used in the combination therapy can be in the form of, for example, a tablet, capsule, suspension, or liquid. Capsules, tablets, and the like can be prepared by conventional methods well known in the art. The compounds are preferably made in the form of a dosage unit containing a specified amount of the compound. Examples of dosage units are tablets or capsules.
  • Pharmaceutical compositions for use in the treatment methods of the present invention can be administered in oral form for all compounds of the composition or by intravenous administration for the HMG Co-A reductase inhibitor and/or other active agent. Oral administration of the pharmaceutical composition comprising the compounds of the combination therapy is preferred.
  • Dosing for oral administration can be with a regimen calling for single daily dose, or for a single dose every other day, or for multiple, spaced doses throughout the day.
  • the unsubstituted polydiallylamine polymer compound and the HMG Co-A reductase inhibitor which comprise the pharmaceutical composition can be administered simultaneously, either in a combined dosage form or in separate dosage forms intended for substantially simultaneous oral administration.
  • the agents which make up the pharmaceutical composition may also be administered sequentially, with either compound being administered by a regimen calling for two-step ingestion.
  • a regimen may call for sequential administration of the compound with spaced- apart ingestion of the separate, active compounds.
  • the time period between the multiple ingestion steps may range from a few minutes to several hours, depending upon the properties of each compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the compound, as well as depending upon the age and condition of the patient.
  • the compounds of the pharmaceutical composition whether administered simultaneously, substantially simultaneously, or sequentially, can involve a regimen calling for administration of the unsubstituted polydiallylamine polymer by oral route and the HMG Co-A reductase inhibitor and/or other active agent by intravenous route.
  • each compound can be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations as described above.
  • the dosage regimen to treat hypercholesterolemia and atherosclerosis and reduce plasma cholesterol with the combination therapy and pharmaceutical compositions of the present invention is selected in accordance with a variety of factors. These include the type, age, weight, sex, diet, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological consideration such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.
  • Initial treatment of a patient suffering from a hyperlipidemic condition such as hypercholesterolemia and atherosclerosis can begin with the dosages indicated above. Treatment should generally be continued as necessary over a period of several weeks to several months or years until the condition has been controlled or eliminated.
  • Patients undergoing treatment with the compounds or compositions disclosed herein can be routinely monitored by, for example, measuring serum LDL and total cholesterol levels by any of the methods well known in the art, to determine the effectiveness of the combination therapy. Continuous analysis of such data permits modification of the treatment regimen during therapy so that optimal effective amounts of each type of agent are administered at any point in time, and so that the duration of treatment can be determined as well.
  • the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amount of unsubstituted polydiallylamine bile acid sequestrant and HMG Co-A reductase inhibitor, which together exhibit therapeutic effectiveness, is administered and so that administration is continued only so long as is necessary to successfully to treat the hyperlipidemic condition such as hypercholesterolemia and atherosclerosis.
  • a potential advantage of the combination therapy disclosed herein may be reduction of the amount of unsubstituted polydiallylamine bile acid sequestrant, HMG Co-A reductase inhibitor, and/or other active agent, or all effective in treating hyperlipidemic conditions such as atherosclerosis and hypercholesterolemia, and in reducing serum cholesterol.
  • the dose can range from about 0.01 mg to about 500 mg, more particularly from about 0.10 mg to about 250 mg, most particularly from about 1 mg to about 100 mg/day, for example, from about 5 mg to about 80 mg/day or any other dose, dependent upon the specific inhibitor, as is known in the art.
  • Suitable dose ranges for treatment with an HMG Co-A reductase inhibitor are available in the Physician's Desk Reference and the Merck Index (Twelfth Edition), the contents of which are incorporated by reference.
  • the unsubstituted polydiallylamine bile acid sequestrant compound can be administered in an amount from about 1 mg/kg/day to about 10 g/kg/day, preferably from about 1 mg/kg/day to about 1 g/kg/day, more preferably from about 1 mg/kg/day to about 200 mg/kg/day, and most preferably from about 1 mg/kg/day to about 100 mg/kg/day.
  • the first and second amounts of the compounds of the combination therapy can be administered by any dual combination of oral/oral or oral/parenteral route.
  • the particular dosage will depend on the individual patient (e.g., the patient's weight and the extent of bile salt removal required).
  • the polymer can be administered either in hydrated or dehydrated form, and can be flavored or added to a food or drink, if desired, to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.
  • suitable forms for administration include pills, tablets, capsules, and powders (e.g., for sprinkling on food).
  • the pill, tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in the esophagus but will allow disintegration of the composition in the stomach and mixing with food to pass into the patient's small intestine.
  • the polymer can be administered alone or in combination with a pharmaceutically acceptable carrier, diluent or excipient substance, such as a solid, liquid or semi-solid material.
  • Suitable carriers, diluents and excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, tragacanth, gelatin, calcium silicate, cellulose e.g., magnesium carbonate or a phospholipid with which the polymer can form a micelle.
  • EXAMPLE 1 PREPARATION OF POLY(DIALLYLAMMONIUM CHLORIDE) Concentrated hydrochloric acid (507.0 g; 37%) was charged to a 5L, 3-neck round bottomed flask and agitated with a mechanical stirrer. The flask was cooled to ⁇ 5°C with an ice bath. Diallylamine (635.0 ml) was added dropwise to the stirring hydrochloric acid over a three hour period using an addition funnel capped with a pierced rubber septum. The stirring solution temperature was maintained at ⁇ 10°C. After the addition was completed, the ice bath was removed and the mixture was allowed to warm to room temperature. Concentrated hydrochloric acid (7.3 g) was added to the solution. Water (368.7 g) was added to the solution and it was allowed to sit overnight.
  • 2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as a 20% aqueous solution. The solution was stirred and heated for another 16 hours, then cooled to room temperature.
  • a solution of 39.3 g of an aqueous solution (68 wt%>) of diallylammonium hydrochloride, 5.3 g of an aqueous solution (73 wt%)of triallylamine hydrochloride and 0.9 g of 2,2'-azobis(2-amidinopropane)dihydrochloride was bubbled with a slow stream of nitrogen for 30 minutes. While stirring, this reaction mixture was added to a solution of 7 g of polyvinylacetate in 300 mL of toluene. The resulting mixture was stirred at room temperature for 45 minutes under nitrogen atmosphere. While stirring, the temperature of the reaction mixture was raised to 60 C and was held at this temperature for 24 hours.
  • the reaction mixture was allowed to cool to room temperature and the polymer particles were collected by filtration. While in the funnel, the filtered particles were successively washed with 300 mL of toluene and 500 mL of methanol. The polymer particles were suspended in 500 mL of methanol, stirred for 50 minutes, and filtered. Subsequently, the particles were suspended in 400 mL of deionized water, stirred for 30 minutes and filtered. The filtered particles were dried at 60 C for 24 hr to yield 15 g of the polymer.
  • Example 1 The polymer solution of Example 1 was crosslinked at 30 mole % as follows: Epichlorohydrin (31.61 mL) was added to 900.0 g of the neutralized polymer solution in a glass beaker, agitated with a magnetic stirrer and covered with polyvinyl film. The gel was allowed to cure for 22 hours. The solid gel was then ground using a grinder. The ground polymer was washed in a static bed manner using a large plastic Buchner funnel lined with filter paper. A second piece of filter paper, perforated with holes, was placed on top of the polymer cake to prevent disturbing the cake when adding wash water. Fresh deionized H 2 O(14 L) was added to the top of the cake and drained under vacuum. The washed polymer was then transferred to glass drying trays and dried in a 60° C forced air oven for several days. The final dry weight was 176.2 g.
  • Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 20 mole %. Epichlorohydrin (21.07 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 163.3 g.
  • Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 4.5 mole %>. Epichlorohydrin (4.74 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 176.2 g.
  • EXAMPLE 7 COPOLYMER OF DIALLYLAMINE AND METHYLENEBISACRYLAMIDE A solution of diallylammoniuim chloride (73.53 g of 68%> aqueous solution), methylenebisacrylamide (2.93 g, 0.019 mol), 2,2'-azobis(2-amidinopropane) dihydrochloride (V50) (0.5 g) and water (27 mL) was heated at 70 °C under a nitrogen atmosphere. Water (100 mL) was added after 15 minutes of reaction. An additional 0.5 g of V50 was added after 3 hours and again after 4 more hours. After keeping the reaction at 70 C for a total of 72 hr, it was cooled to room temperature.
  • V50 2,2'-azobis(2-amidinopropane) dihydrochloride
  • EXAMPLE 9 COPOLYMER OF DIALLYLAMINE, ACRYLAMIDE AND METHYLENEBISACRYLAMIDE
  • EXAMPLE 10 COPOLYMER OF DIALLYLAMINE, A FUNCTIONALIZED ACRYLIC ESTER AND AN ACRYLIC ESTER CROSS- LINKING MONOMER
  • diallylammonium chloride (14.7 g of 68%> aqueous)
  • 2- hydroxyethylmethacrylate (9.76 g)
  • ethyleneglycol dimethacrylate (2.97 g)
  • MeOH 25 mL
  • 2,2'-azobis(2-amidinopropane) dihydrochloride (0.07 g of an 18.8%) aqueous solution) was heated at 65 °C under a nitrogen atmosphere for 20 hours.
  • the resulting material was suspended in methanol (500 mL), stirred for 15 minutes and filtered.
  • the polymer was similarly washed three times with water (500 mL). This methanol wash and filtration were repeated twice more. The washed polymer was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.1. Filtration and drying at 60° C in a forced-air oven gave 13.9 g of a solid.
  • EXAMPLE 11 COPOLYMER OF DIALLYLAMINE, A FUNCTIONALIZED ACRYLIC ESTER AND AN ACRYLIC ESTER CROSS-
  • EXAMPLE 12 COPOLYMER OF DIALLYLAMINE AND GLYCIDYLMETHACRYLATE A solution of diallylammonium chloride (29.42 g of a 68%> aqueous solution), glycidylmethacrylate (2.13 g), MeOH (25 mL), and 2,2'-azobis(2-amidinopropane) dihydrochloride (1.18 g of an 18.8% aqueous solution) was heated at 65 °C under a nitrogen atmosphere for 12 hours. After cooling to room temperature, methanol (25 mL) was added and the pH of the solution was adjusted to 10 with the addition of 50%) aqueous NaOH, and allowed to stir at room temperature. The reaction solution turned to a solid mass after about 2 hours, and was allowed to stand for 22 hours. The resulting gel, was suspended in MeOH
  • EXAMPLE 13 COPOLYMER OF ALLYL AMINE, DIALLYLAMINE,
  • TRIALLYLAMINE AND A BIS(DIALLYLAMINO)ALKYLENE SALT A solution of allylammonium chloride (25.0 g of a 60%> aqueous solution), diallylammonium chloride (66.81 g of a 67% aqueous solution), triallylammonium chloride (40.87 g of a 68% aqueous solution), 1 ,6-bis(diallylmethylammoniium) hexane dibromide (5.0 g), and 2,2'-azobis(2-amidinopropane) dihydrochloride (4.28 g of a 20%) aqueous solution), was heated at 55 °C under a nitrogen atmosphere for 18 hours and at 80°C for 2 hours.
  • EXAMPLE 14 COPOLYMER OF ALLYLAMINE AND DIALLYLAMINE A solution of allylammonium chloride (54.71 g of a 57% aqueous solution), diallylammonium chloride (132.96 g of a 67%o aqueous solution), and 2,2'-azobis(2- amidinopropane)dihydrochloride (6.01 g of a 20% aqueous solution), was heated at 55 °C under a nitrogen atmosphere for 36 hours. Another portion of 2,2'-azobis(2- amidinopropane)dihydrochloride (6.01 g of a 20%) aqueous solution) was added after the first 18 hours.
  • EXAMPLE 15 COPOLYMER OF ALLYLAMINE, DIALLYLAMINE AND A BIS(DIALLYLAM ⁇ NO) ALKYLENE
  • EXAMPLE 16 IN VIVO TESTING Male Golden Syrian Hamsters were group housed in shoe box cages and acclimated for approximately 1 week in our animal facility. Animals were fed rodent chow (brown color) and water ad libitum. The hamsters were then transferred to metabolism cages and housed individually. Following a 24 hour fast (water ad libitum), animals were presented a casein-based purified diet (white color) with 10%) fat added plus the drug to be evaluated. Fecal material was collected from 9 hours after the casein-based diet was presented for 39 additional hours. The white fecal pellets (drug-containing casein-based diet) were lyophilized and ground to a homogeneous powder.
  • crosslinked polydiallylamine is a highly potent bile acid sequestrant, with in vivo activity greater than current commercial products, Colestipol and Cholestyramine.

Abstract

L'invention concerne des méthodes permettant de traiter l'hypercholestérolémie et l'athérosclérose, et de réduire le cholestérol sérique chez un mammifère. Les méthodes de cette invention consistent notamment à administrer à ce mammifère une première quantité d'un composé chélateur des acides biliaires, ce composé étant un polymère de polydiallylamine non substitué, ainsi qu'une seconde quantité d'un composé inhibiteur de la HMG Co-A réductase, ces première et seconde quantités formant par ailleurs une quantité efficace d'un point de vue thérapeutique. Cette invention concerne également des compositions pharmaceutiques utiles pour traiter l'hypercholestérolémie et l'athérosclérose, et pour réduire le cholestérol sérique. Ces compositions pharmaceutiques renferment une combinaison d'une première quantité d'un composé polymère de polydiallylamine non substitué et d'une seconde quantité d'un composé inhibiteur de la HMG Co-A réductase, ces première et seconde quantités formant par ailleurs une quantité efficace d'un point de vue thérapeutique. Les compositions pharmaceutiques de la présente invention peuvent éventuellement renfermer un excipient acceptable d'un point de vue pharmaceutique.
PCT/US1999/010637 1999-05-13 1999-05-13 Polytherapie pour traiter l'hypercholesterolemie WO2000069446A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1999/010637 WO2000069446A1 (fr) 1999-05-13 1999-05-13 Polytherapie pour traiter l'hypercholesterolemie
AU39903/99A AU3990399A (en) 1999-05-13 1999-05-13 Combination therapy for treating hypercholesterolemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/010637 WO2000069446A1 (fr) 1999-05-13 1999-05-13 Polytherapie pour traiter l'hypercholesterolemie

Publications (1)

Publication Number Publication Date
WO2000069446A1 true WO2000069446A1 (fr) 2000-11-23

Family

ID=22272760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010637 WO2000069446A1 (fr) 1999-05-13 1999-05-13 Polytherapie pour traiter l'hypercholesterolemie

Country Status (2)

Country Link
AU (1) AU3990399A (fr)
WO (1) WO2000069446A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029107A2 (fr) * 1996-12-30 1998-07-09 Geltex Pharmaceuticals, Inc. Chelateurs d'acide biliaire a base de poly(diallylamine)
GB2329334A (en) * 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029107A2 (fr) * 1996-12-30 1998-07-09 Geltex Pharmaceuticals, Inc. Chelateurs d'acide biliaire a base de poly(diallylamine)
GB2329334A (en) * 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés

Also Published As

Publication number Publication date
AU3990399A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
US6264938B1 (en) Combination therapy for treating hypercholestrolemia
JP4499363B2 (ja) 血清グルコースの減少方法
US6423754B1 (en) Method for treating hypercholesterolemia with polyallylamine polymers
US6203785B1 (en) Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) Interpenetrating polymer networks for sequestration of bile acids
US6726905B1 (en) Poly (diallylamines)-based phosphate binders
US20030039627A1 (en) Method for treating gout and binding uric acid
US20020187120A1 (en) Method for treating gout and reducing serum uric acid
AU2002257145A1 (en) Method for lowering serum glucose
ZA200308063B (en) Method of lowering serum glucose.
US20020182168A1 (en) Method for reducing copper levels and treating copper toxicosis
WO2000069446A1 (fr) Polytherapie pour traiter l'hypercholesterolemie
WO2000069445A1 (fr) Polytherapie pour traiter l'hypercholesterolemie
EP1923064B1 (fr) Utilisation des aminopolymères pour réduire le glucose sérique
MXPA00004329A (en) Unsubstituted polydiallylamine for treating hypercholesterolemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase